Disparities in adoption of new diabetic therapies with cardiovascular benefits

•Given the known cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), we analyzed treatment rates of these medications across medical comorbidities and sociodemographic characteristics to understand provider prescribing pattern among patients with commercial insurance.•We identified pharmacy fills of either GLP1RA or SGLT2i within 180 days of an index clinic visit with primary care or endocrinology.•We found that patients with high-risk comorbidities, Black, Hispanic or Asian patients and those with low-income were less likely to be treated with GLP1RA/SGLT2i therapy.